PCA
NBIX icon

Pallas Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Pallas Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Sell
9,265
-2,868
-24% -$426K 0.05% 259
2026
Q1 		$1.6M Sell
12,133
-4,650
-28% -$617K 0.06% 234
2025
Q4 		$2.38M Buy
16,783
+1,270
+8% +$184K 0.08% 195
2025
Q3 		$2.18M Buy
15,513
+6,120
+65% +$829K 0.08% 196
2025
Q2 		$1.18M Buy
9,393
+6,793
+261% +$779K 0.05% 296
2025
Q1 		$288K Sell
2,600
-5,073
-66% -$643K 0.01% 596
2024
Q4 		$1.05M Buy
7,673
+1,225
+19% +$152K 0.04% 226
2024
Q3 		$745K Buy
6,448
+3,350
+108% +$459K 0.03% 276
2024
Q2 		$447K Buy
3,098
+647
+26% +$88.7K 0.02% 329
2024
Q1 		$338K Buy
+2,451
New +$335K 0.01% 342

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pallas Capital Advisors's NBIX Position: Q2 2026 in Review

Pallas Capital Advisors reduced its Neurocrine Biosciences (NBIX) stake by 24% in Q2 2026, selling an estimated $426K and leaving 9,265 shares worth $1.56M. The position accounts for 0.05% of the portfolio, ranked #259.

Pallas Capital Advisors first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.38M in Q4 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Pallas Capital Advisors held 9,265 shares of Neurocrine Biosciences worth $1.56M as of Q2 2026.
  • Pallas Capital Advisors sold 2,868 Neurocrine Biosciences shares in Q2 2026, an estimated $426K.
  • Neurocrine Biosciences made up 0.05% of Pallas Capital Advisors's portfolio in Q2 2026, its #259 holding.
  • Pallas Capital Advisors first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
  • Pallas Capital Advisors's Neurocrine Biosciences position peaked at $2.38M in Q4 2025.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.